Actively Recruiting
Single Chemotherapy Bladder Instillation After Endoscopic Treatment for Upper Tract Urothelial Carcinoma to Reduce Bladder Recurrence
Led by Carmel Medical Center · Updated on 2023-12-20
264
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients suspected of having upper tract urothelial carcinoma UTUC to evaluate the safety and cancer-related outcomes of a single chemotherapy bladder instillation after endoscopic treatment. The study aims to determine if this single chemotherapy dose given after ureteroscopy URS can reduce the chance of bladder cancer recurrence inside the bladder, known as intravesical recurrence IVR. Participants will receive a single bladder instillation of chemotherapy, either Mitomycin or Gemcitabine, within 24 hours after URS. Some participants will receive the chemotherapy instillation while others will receive a placebo instillation of saline. The study uses a randomized design with single masking to compare the effects of the chemotherapy against saline. Patients will undergo routine follow-up including white light cystoscopy, and those with suspected bladder recurrence will receive further treatment such as transurethral resection of bladder tumor TURBT. During the study, participants will be monitored for recurrence of bladder cancer over one and two years, measuring IVR-free survival and disease-free survival as main outcomes. Adverse events of grade 3 or higher will also be tracked over two years. The study involves regular cystoscopy and imaging to detect any bladder recurrence. Participants will be followed for up to two years after treatment to assess the long-term effects and safety of the chemotherapy instillation.
CONDITIONS
Brief Title
POST URS Chemotherapy Instillation
Research Team
Y
Yuval Freifeld, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here